GYRE THERAPEUTICS INC

View in Terminal

Loading quotes...

Forecast

The analysts' average price target is €32.28 (+672.25%). The median is €32.28 (+672.25%).

Buy	10
Hold	4
Sell	0

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2023, GYRE THERAPEUTICS INC has already paid €0.22 in dividends. The last payout was in January 2023.

Financials

In the last quarter, GYRE THERAPEUTICS INC had revenue of €0 and net profit of -€19.88m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-19.88m	7.54%
EBITDA	-21.7m	23.50%

Fundamentals

Metric	Value
Market capitalization	€451.03m
Number of shares	37.14m
52-week high/low	€24.58 - €7.82
Dividends	No
Beta	1.39
P/E ratio	-1.79
PEG ratio	-0.01
P/B ratio	2.53
P/S ratio	42.32

Company profile

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.